BLU-5937 50 mg for Coughing

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Coughing+1 More
BLU-5937 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Eligible Conditions
  • Coughing

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Week 24

Baseline, Week 24
Change from Baseline in Cough Severity Visual Analogue Scale at Week 24
Change from Baseline in the Leicester Cough Questionnaire (LCQ) Total Score at Week 24
Percentage of Participants With a ≥1.3-point Increase From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Week 24
Percentage of Participants With ≥ 30mm Reduction, ≥ 20mm Reduction From Baseline in Cough Severity Visual Analog Scale (VAS) at Week 24
Percentage of Participants With ≥30%, ≥50%, and ≥70% Reduction From Baseline in 24-Hour Cough Frequency at Week 24
Week 24
Coughing

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

3 Treatment Groups

BLU-5937 50 mg
1 of 3
BLU-5937 25 mg
1 of 3
Placebo
1 of 3

Experimental Treatment

Non-Treatment Group

675 Total Participants · 3 Treatment Groups

Primary Treatment: BLU-5937 50 mg · Has Placebo Group · Phase 3

BLU-5937 50 mg
Drug
Experimental Group · 1 Intervention: BLU-5937 · Intervention Types: Drug
BLU-5937 25 mg
Drug
Experimental Group · 1 Intervention: BLU-5937 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BLU-5937
2020
Completed Phase 2
~550

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: week 24

Who is running the clinical trial?

Bellus Health IncLead Sponsor
13 Previous Clinical Trials
4,217 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 1st, 2021

Last Reviewed: November 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.